(Q37062140)

18 August 2017

0 references

1 reference

title

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis (English)

1 reference

18 August 2017

0 references

1 reference

David Chu

1

1 reference

18 August 2017

Mario E Lacouture

series ordinal

2

1 reference

18 August 2017

Triantafillos Fillos

series ordinal

3

1 reference

18 August 2017

Shenhong Wu

series ordinal

4

1 reference

18 August 2017

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

47

1 reference

18 August 2017

2

1 reference

18 August 2017

176-186

1 reference

BAY 43-9006: preclinical data

18 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Epithelial-stromal interactions in basal cell cancer: the PDGF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Current Canadian experience with capecitabine: partnering with patients to optimize therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Bevacizumab in the management of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

The kinase inhibitor imatinib--an immunosuppressive drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701765675

10.1080/02841860701765675

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference